Virus News and Research

Latest Virus News and Research

New genetic resource to accelerate development of novel treatments for diseases

A new genetic resource from an international research consortium is expected to accelerate the development of new cures and treatments for a wide range of human diseases. This project, called the mouse "Collaborative Cross" (CC) resource, will increase the likelihood that experiments conducted in mice will advance our understanding of human biology.

17 Feb 2012

U of A researcher discovers new vaccine against HCV

A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.

17 Feb 2012

IKK2 enzyme plays a key role in proliferation of lung cancer cells

Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.

17 Feb 2012

New way to improve vaccines against cancer and infectious diseases

Research groups from Charité Universitätsmedizin Berlin and the University of Geneva have discovered a new way of improving vaccines against infectious diseases and for use in cancer therapies. Scientists have shown a basic new mechanism that stimulates the body's own alarm signals in case of viral infection to animate the immune system to maximum performance.

17 Feb 2012

MV-GFP extends survival of animals with medulloblastoma

A strain of measles virus engineered to kill cancer cells prolongs survival in a model of medulloblastoma that is disseminated in the fluid around the brain, according to a new study by researchers at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and the Mayo Clinic.

16 Feb 2012

Reuters examines upcoming WHO meeting to discuss debate over bird flu research

Bird flu experts are scheduled to begin a two-day meeting at the WHO in Geneva on Thursday "to try to settle an unprecedented row over a call to censor publication of two scientific studies which detail how to mutate H5N1 bird flu viruses into a form that could cause a deadly human pandemic," Reuters reports in an article describing the debate in detail.

16 Feb 2012

WSU's novel gene-therapy for blindness receives $250,000 FFB grant

Technology to restore vision through the use of a component of green algae - developed by a Wayne State University professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute - has attracted additional funding for therapy development.

16 Feb 2012

Bird flu controversy an opportunity to set a higher tone for public debate

In this Huffington Post opinion piece, Leslie Gerwin, associate director of law and public affairs at Princeton University, reflects on the recent controversy over whether to research and publish data about potentially dangerous strains of the H5N1 bird flu virus, writing, "I am disturbed that so much coverage of this dispute -- so deserving of sober consideration -- is fixated on fear mongering."

15 Feb 2012

Tissues in SIV-infected monkeys can ramp up production of Tregs

Tissue in monkeys infected with a close relative of HIV can ramp up production of a type of T cell that actually weakens the body's attack against the invading virus. The discovery, in lymph nodes draining the intestinal tract, could help explain how the HIV virus evades the body's immune defenses.

15 Feb 2012

Stress protein effectively activates replication of HBV in liver cells

People who have received a donor organ need lifelong immunosuppressant drugs to keep their immune system from attacking the foreign tissue. However, with a suppressed immune system, many infectious agents turn into a threat. Infections such as with human cytomegalovirus and a certain type of human polyomavirus frequently cause complications in transplant recipients.

14 Feb 2012

Promising compound may counteract HIV's ability to hijack CD59 protein

One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.

14 Feb 2012

Fair trade agreement between E.U., India could impede access to medicine for world's poor

"Current negotiations on a free trade agreement (FTA) between the European Union and India are causing serious concern in many quarters over future access to cheap generic medicines used to treat some of the world's great public health threats: HIV, tuberculosis and malaria, and also cancer," Philippe Douste-Blazy, U.N. special adviser on innovative financing for development and chair of UNITAID, and Denis Broun, executive director of UNITAID, write in this post in the Guardian's "Poverty Matters Blog."

14 Feb 2012

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.

14 Feb 2012

Scientists test new 'therapeutic vaccine' against HIV on volunteers

Scientists from the Antwerp Institute of Tropical Medicine, Antwerp University Hospital and Antwerp University have tested a new 'therapeutic vaccine' against HIV on volunteers. The participants were so to say vaccinated with their own cells.

13 Feb 2012

Starving HIV virus could be the basis for future therapy: Study

In a medical breakthrough researchers at NYU Langone Medical Center and colleagues have shown how some cells in the body can repel attacks from HIV by starving the virus of the building blocks of life.

13 Feb 2012

Tenofovir associated with significant risk of kidney damage and chronic kidney disease

Tenofovir, one of the most effective and commonly prescribed antiretroviral medications for HIV/AIDS, is associated with a significant risk of kidney damage and chronic kidney disease that increases over time, according to a study of more than 10,000 patients led by researchers at the San Francisco VA Medical Center and the University of California, San Francisco (UCSF).

13 Feb 2012

DARPA awards fourth milestone payment of $3.56M to Medicago

Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the fourth milestone payment of US$3.56 million from the Defense Advanced Research Projects Agency.

13 Feb 2012

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.

13 Feb 2012

SAMHD1 protein cuts off raw material that HIV needs to create DNA and replicate

A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online in Nature Immunology.

13 Feb 2012

Study reveals how SAMHD1 works to protect dendritic cells from HIV virus

A novel discovery by researchers at NYU Langone Medical Center and colleagues reveals a mechanism by which the immune system tries to halt the spread of HIV. Harnessing this mechanism may open up new paths for therapeutic research aimed at slowing the virus' progression to AIDS. The study appears online ahead of print today in Nature Immunology.

12 Feb 2012